Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034

Carlyn Rose C. Tan, Stefan K. Barta, Jeannette Lee, Michelle A. Rudek, Joseph A. Sparano, Ariela Noy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drug–drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Nov 22 2017

Fingerprint

AIDS-Related Lymphoma
Drug Therapy
HIV
Therapeutics
CD4 Lymphocyte Count
Viral Load
Lymphoma
B-Lymphocytes
Pharmacokinetics
Research Personnel
Incidence

Keywords

  • AIDS
  • chemotherapy
  • combination antiretroviral therapy
  • dose-adjusted EPOCH
  • HIV
  • HIV-associated lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH : a comparison within one prospective trial AMC034. / Tan, Carlyn Rose C.; Barta, Stefan K.; Lee, Jeannette; Rudek, Michelle A.; Sparano, Joseph A.; Noy, Ariela.

In: Leukemia and Lymphoma, 22.11.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{671ca11c7afb499dae349deec003a326,
title = "Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034",
abstract = "Drug–drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.",
keywords = "AIDS, chemotherapy, combination antiretroviral therapy, dose-adjusted EPOCH, HIV, HIV-associated lymphoma",
author = "Tan, {Carlyn Rose C.} and Barta, {Stefan K.} and Jeannette Lee and Rudek, {Michelle A.} and Sparano, {Joseph A.} and Ariela Noy",
year = "2017",
month = "11",
day = "22",
doi = "10.1080/10428194.2017.1403597",
language = "English (US)",
pages = "1--10",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH

T2 - a comparison within one prospective trial AMC034

AU - Tan, Carlyn Rose C.

AU - Barta, Stefan K.

AU - Lee, Jeannette

AU - Rudek, Michelle A.

AU - Sparano, Joseph A.

AU - Noy, Ariela

PY - 2017/11/22

Y1 - 2017/11/22

N2 - Drug–drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.

AB - Drug–drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.

KW - AIDS

KW - chemotherapy

KW - combination antiretroviral therapy

KW - dose-adjusted EPOCH

KW - HIV

KW - HIV-associated lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85034667856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034667856&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1403597

DO - 10.1080/10428194.2017.1403597

M3 - Article

C2 - 29160731

AN - SCOPUS:85034667856

SP - 1

EP - 10

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -